USFDAMay 20, 2026, 06:02 AM
Belite Bio Initiates Rolling FDA NDA for STGD1 Drug; Q1 Net Loss $26.9M
AI Summary
Belite Bio announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. FDA for tinlarebant for Stargardt disease type 1 (STGD1) in April 2026, with completion anticipated in the second quarter of 2026. The company is also advancing commercialization preparations for STGD1, having completed hiring for key leadership positions. For the first quarter ended March 31, 2026, Belite Bio reported a GAAP net loss of $26.9 million, an increase from $14.3 million in the prior year, driven by higher R&D and SG&A expenses. The company maintained a strong cash position with $798.6 million in cash and investments.
Key Highlights
- Belite Bio initiated a rolling NDA submission to the FDA for tinlarebant for STGD1 in April 2026, expected to complete in Q2 2026.
- Commercialization preparation for STGD1 is underway, with all key commercial leadership positions hired.
- Cash and cash equivalents, U.S. treasury bills and notes totaled $798.6 million as of March 31, 2026.
- GAAP net loss for Q1 2026 was $26.9 million, compared to $14.3 million for Q1 2025.
- Research and development expenses increased to $15.7 million in Q1 2026 from $9.4 million in Q1 2025.
- Selling, general and administrative expenses rose to $17.0 million in Q1 2026 from $6.1 million in Q1 2025.
- DRAGON II trial enrollment for STGD1 completed with 73 subjects in early March 2026.
- PHOENIX trial enrollment for Geographic Atrophy (GA) completed with 530 subjects.
Price Impact
More from BLTE